

#### Routes to Diagnosis Results

## UKACR and NCIN Joint Conference

#### 17<sup>th</sup> -18<sup>th</sup> June 2010

#### Lucy Elliss-Brookes

Associate Director, Commissioning and Cancer Intelligence Avon, Somerset & Wiltshire Cancer Service



#### **Routes to Diagnosis**



- Background
  - People involved
  - Rationale
  - Project questions
  - Project approach, scope and methodology
- Selected results
- Discussion
- Next steps



#### **People involved**



- Project Manager:
- Analytical lead:
- Clinical Adviser:

Lucy Elliss-Brookes, NCIN Alexander Ives, SWPHO Professor Sir Mike Richards

- NCIN: Chris Carrigan, Sean McPhail
- South West Public Health Observatory: Matt Greenslade, Andy Pring, Carlos Rocha, Tariq Malik, Dr Julia Verne,, Matt Iles
- Cancer Research UK: Sara Hiom
- University of Bristol: Dr Willie Hamilton
- NatCanSat: Helen Forbes



#### Rationale for project



- Simple questions
  - How do people come to get diagnosed with cancer?
  - Are late diagnoses arising in cases where patients have not gone through the screening or suspected cancer route?
- National Awareness and Early Diagnosis Initiative (NAEDI)
- Better understand the different routes to diagnosis through urgent referral, screening and other pathways
- Use existing data



### **Project questions**



- 1. Is it possible to define the routes to diagnosis for patients diagnosed with cancer?
- 2. Can we work backwards through the cancer journey and ascertain the sequence of events that take people to a diagnosis, through inpatients, outpatients, A&E and screening?
- 3. Are there differences for age, sex, ethnicity, deprivation and geographical area?
- 4. Does route to diagnosis impact on the clinical outcome?



## Project approach, scope and methodology



- Starting point date of cancer registration (data for 2007)
- All malignant tumours (C00 to C97) and some in situ (D05 & D06)
- Follow the patient journey backwards through the data
- Hospital Episodes Statistics data for 2006 and 2007 (inpatient and outpatient)
- Include cancer waiting times and screen detected flags
- Following the patient not the tumour
- Set of rules defined to identify sequence of events
- Combine into simple groupings to enable analysis
- Pilot approach for England using South West data



#### **Eight Routes to Diagnosis**



- **GP/Outpatient referral**: includes routine and urgent referrals
- Two Week Wait: urgent GP referrals with a suspicion of cancer
- **Emergency presentation**: emergency route via A&E, emergency GP or consultant outpatient referral, emergency transfer etc
- **Other outpatient**: elective route starting with an outpatient appointment that is a self, consultant, other or unknown referral
- Screen detected: breast or cervical
- Inpatient elective: where no earlier information found
- **DCO**: diagnosis by death certificate only
- Unknown: no data available from HES, CWT or screening



Routes to Diagnosis	GP/ OP referral	Two Week Wait	Emergency presentation	Other outpatient	Screen detected	Inpatient elective	80	Unknown	Total	Number of patients
Acute leukaemia	17%	3%	61%	12%	0%	4%	0%	4%	100%	380
Bladder	22%	36%	18%	13%	0%	6%	1%	5%	100%	1,167
Brain & ONS	18%	2%	49%	20%	0%	5%	0%	5%	100%	740
Breast	8%	40%	5%	5%		2%	0%	13%	100%	5,646
Cervix	21%	17%	12%	8%	23%	3%	1%	15%	100%	308
Chronicleukaemia	26%	6%	45%	13%	0%	4%	1%	4%	100%	629
Colorectal	19%	29%	24%	12%	0%	8%	0%	7%	100%	4,515
Kidney	22%	26%	23%	16%	0%	5%	0%	8%	100%	928
Larynx	35%	34%	8%	14%	0%	5%	0%	3%	100%	216
Lung	15%	26%	38%	10%	0%	4%	1%	7%	100%	3,893
Melanoma	23%	39%	4%	8%	0%	5%	0%	22%	100%	1,686
Multiple myeloma	20%	14%	44%	13%	0%	4%	1%	5%	100%	606
Non-Hodgkin's lymphoma	25%	22%	25%	13%	0%	6%	1%	9%	100%	1,349
Oesophagus	15%	32%	21%	14%	0%	13%	0%	4%	100%	912
Oral	32%	27%	5%	14%	0%	4%	1%	17%	100%	458
Ovary	20%	29%	28%	11%	0%	3%	1%	8%	100%	853
Pancreas	13%	20%	45%	10%	0%	5%	1%	7%	100%	917
Prostate	26%	28%	11%	11%	0%	7%	0%	16%	100%	4,865
Stomach	14%	24%	31%	13%	0%	11%	1%	6%	100%	801
tbc(other)	21%	18%	34%	12%	0%	4%	1%	9%	100%	4,323
Testis	14%	47%	9%	15%	0%	4%	0%	11%	100%	259
Uterus	28%	36%	8%	12%	0%	5%	0%	12%	100%	918
Total	19%	28%	22%	11%	5%	5%	1%	10%	100%	36,369



All cancer Routes to Diagnosis: by cancer type

All malignant registrations South West 2007 excluding C44 and multiples





Breast cancer	<b>GP/ OP referral</b>	Two Week Wait	Emergency presentation	Other outpatient	Screen detected	Inpatient elective	80	Unknown	Total	Number of patients
15-19	0%	0%	0%	100%	0%	0%	0%	0%	100%	1
20-24	0%	0%	0%	0%	0%	0%	0%	100%	100%	1
25-29	27%	47%	0%	0%	0%	0%	0%	27%	100%	15
30-34	20%	43%	0%	4%	0%	4%	0%	30%	100%	56
35-39	14%	50%	3%	7%	0%	1%	0%	25%	100%	169
40-44	11%	53%	3%	8%	1%	1%	0%	23%	100%	318
45-49	12%	55%	2%	7%	6%	1%	0%	18%	100%	432
50-54	7%	27%	1%	4%	47%	1%	0%	13%	100%	545
55-59	6%	25%	1%	4%	50%	1%	0%	11%	100%	628
60-64	5%	25%	2%	5%	51%	2%	0%	10%	100%	772
65-69	4%	23%	3%	4%	57%	1%	0%	7%	100%	715
70-74	9%	45%	5%	5%	25%	1%	0%	10%	100%	480
75-79	7%	56%	7%	4%	9%	4%	0%	13%	100%	587
80-84	9%	56%	9%	6%	3%	3%	1%	13%	100%	433
85+	8%	54%	20%	2%	0%	2%	2%	13%	100%	494
Total	8%	40%	5%	5%	28%	2%	0%	13%	100%	5,646



Breast Routes to Diagnosis: by age band

All malignant registrations South West 2007 excluding C44 and multiples



Nucceil Nucceil Cancer Research Institute

## Lung Routes to Diagnosis: by deprivation quintile



All malignant registrations, South West 2007, excluding C44 and multiples

Lung cancer	GP/ OP referral	Two Week Wait	Emergency presentation	Other outpatient	Screen detected	Inpatient elective	8	Unknown	Total	Number of patients
5 (least deprived)	17%	24%	37%	10%	0%	4%	1%	7%	100%	631
4	16%	26%	37%	10%	0%	4%	1%	7%	100%	872
3	14%	26%	38%	11%	0%	3%	1%	7%	100%	1,041
2	14%	27%	40%	9%	0%	3%	1%	6%	100%	917
1 (most deprived)	13%	25%	41%	10%	0%	4%	1%	6%	100%	432
Total	15%	26%	38%	10%	0%	4%	1%	7%	100%	3,893



## Relative one year survival: by cancer type


Malignant registrations, South West 2007, excluding multiples and DCOs



	GP/OP refer	ral (+TWW)	Emerç	jency	Other	route	EUROCARE
Cancer type	Relative Survival	95% Cls	Relative Survival	95% Cls	Relative Survival	95% Cls	Relative Survival
Acute leukaemia	39.7	(28.1 - 51)	39.4	(32.9 - 45.8)	40.4	(29 - 51.5)	
Bladder	78.3	(74.6 - 81.5)	34.0	(27.3 - 40.8)	79.2	(73.2 - 84)	85.3
Brain & CNS	68.4	(60.1 - 75.4)	34.0	(29.1 - 38.9)	60.6	(53.6 - 66.8)	39.1
Breast	97.7	(96.8 - 98.4)	50.8	(44.4 - 56.9)	98.2	(97.5 - 98.8)	95
Colorectal	84.5	(82.7 - 86.2)	48.4	(45.2 - 51.5)	79.5	(76.9 - 81.9)	74.7
Kidney	81.1	(76.8 - 84.7)	24.0	(18.4 - 30)	72.4	(66.1 - 77.7)	74.7
Lung	39.8	(37.4 - 42.3)	8.9	7.6 - 10.3)	32.4	(29.1 - 35.7)	36.1
Multiple myeloma	83.6	(76.8 - 88.5)	53.1	(46.5 - 59.2)	73.0	(63.7 - 80.3)	70.5
Non-Hodgkin's lymphoma	86.6	(83.2 - 89.3)	43.7	(38.1 - 49.1)	80.9	(76 - 84.9)	73.1
Oesophagus	43.8	(38.9 - 48.6)	22.4	(16.7 - 28.7)	45.5	(39.5 - 51.4)	36.3
Other	81.1	(79.8 - 82.4)	27.2	(25.2 - 29.2)	77.8	(76.1 - 79.5)	
Ovary	83.4	(79.1 - 86.9)	38.8	(32.4 - 45.1)	72.1	(64.7 - 78.3)	70.7
Pancreas	21.0	(16.6 - 25.9)	6.0	(4.1 - 8.6)	22.3	(16.8 - 28.4)	19.2
Prostate	98.0	(97 - 98.7)	48.2	(43.6 - 52.7)	98.3	(96.9 - 99.1)	92.2
Stomach	49.1	(43.1 - 54.8)	17.7	(13.3 - 22.8)	47.6	(41 - 54)	44.1

Using information to improve quality & choice

TH OBS






# Relative one year survival: by age band



Malignant registrations, South West 2007, excluding multiples and DCOs

	GP/C	P referral	Two W	/eek Wait	Eme	ergency	Other route		
Age Band	Relative Survival	95% Cls							
00-49	92.4	(90.3 - 94.1)	95.2	(93.8 - 96.3)	69.8	(65.8 - 73.4)	91.7	(90.1 - 93.1)	
50-54	83.8	(79.3 - 87.3)	87.6	(84.3 - 90.3)	46	(39.4 - 52.3)	89.8	(87.5 - 91.7)	
55-59	83.2	(79.8 - 86)	84.3	(81.5 - 86.6)	43.8	(38.9 - 48.7)	85.7	(83.5 - 87.6)	
60-64	81.9	(79 - 84.4)	83.0	(80.7 - 85.1)	37.1	(33.4 - 40.8)	84.8	(82.8 - 86.5)	
65-69	81.1	(78.4 - 83.5)	79.9	(77.5 - 82)	32.8	(29.4 - 36.3)	83.8	(81.8 - 85.5)	
70-74	80.3	(77.5 - 82.7)	80.9	(78.6 - 83)	34.7	(31.7 - 37.7)	77.0	(74.6 - 79.3)	
75-79	72.9	(69.9 - 75.7)	76.6	(74.2 - 78.8)	23.6	(21.3 - 26)	71.3	(68.5 - 73.8)	
80-84	70.1	(66.3 - 73.5)	69.3	(66.2 - 72.2)	19.2	(17.2 - 21.3)	64.0	(60.7 - 67.1)	
85+	58.9	(54 - 63.5)	67.1	(63.5 - 70.5)	16.7	(15 - 18.4)	45.7	(41.9 - 49.5)	








## Relative one year survival: by deprivation quintile



Malignant registrations, South West 2007, excluding multiples and DCOs

	GP/OP referral		Two W	/eek Wait	Eme	ergency	Other route		
Deprivation	Relative Survival	95% Cls							
5 (least)	80.6	(78.3 - 82.7)	83.7	(81.7 - 85.4)	35.8	(33.3 - 38.2)	83.1	(81.4 - 84.6)	
4	80.1	(78 - 82)	82.2	(80.5 - 83.8)	29.6	(27.6 - 31.7)	80.2	(78.6 - 81.8)	
3	79.6	(77.5 - 81.5)	80.4	(78.8 - 82)	27.8	(25.9 - 29.7)	79.4	(77.7 - 80.9)	
2	77.3	(74.7 - 79.6)	77.8	(75.7 - 79.8)	27.8	(25.7 - 30)	76.9	(74.8 - 78.9)	
1 (most)	75.5	(71.1 - 79.3)	78.5	(75.3 - 81.4)	25.2	(22 - 28.4)	75.3	(71.8 - 78.5)	







#### Next steps



- Methodology to be quality assured by another Cancer Registry
- Awaiting South West A&E data
- Further analysis
  - Unknowns
  - Multiples
  - In Situ tumours
- National data obtained & being processed (including Two Week Wait and Screening)
- Test methodology with national data
- National analysis & report planned September 2010





#### Discussion



- Data confirms what we already know
- Further survival analysis possible
- Percentage of Two Week Wait referrals (28%)
- Explore limitations of methodology
  - unknowns, inpatient elective, other outpatient
- Potential expansion of project
  - primary care data including primary care audit, treatments, stage at diagnosis, international benchmarking







#### lucy.elliss-brookes@nhs.net

#### www.ncin.org.uk

